Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
DNA, RNA & Cells
Filter     Order     Display # 
Date Item Title Hits
12 Mar 2010 FDA Allows IND for Bio-Path Holdings' Liposomal Grb-2 19
11 Mar 2010 Pharmaxis completes phase II clinical study with ASM8 in asthma patients 94
10 Mar 2010 Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B 45
10 Mar 2010 TRANSGENE SIGNS AN EXCLUSIVE OPTION AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF ITS IMMUNOTHERAPY PRODUCT TG4010 61
09 Mar 2010 Aastrom Announces Treatment of Final Patient in IMPACT-DCM Surgical Clinical Trial 40
09 Mar 2010 Ark withdraws Cerepro MAA after SAG-O requests further trial before approval 54
08 Mar 2010 Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx 52
05 Mar 2010 MOLOGEN AG receives approval for clinical study with cancer drug MGN1703 70
05 Mar 2010 ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS 68
04 Mar 2010 Argos Therapeutics Publishes Positive Immune Response, Safety and Manufacturing Data for its Arcelis HIV Program in Clinical Immunology 62
03 Mar 2010 Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 50
03 Mar 2010 New Research Reveals Mechanism By Which TNFerade(TM) Suppresses Metastases 59
02 Mar 2010 Pluristem Therapeutics Receives DSMB Approval to Advance to Final Dose Level With PLX-PAD 57
01 Mar 2010 Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007 61
25 Feb 2010 The European Medicines Agency is in Overall Agreement with OncoGenex Pharmaceuticals' Development Plan for OGX-011 in Patients with Metastatic Castrate-Resistant Prostate Cancer 64
25 Feb 2010 Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122 11
24 Feb 2010 Aastrom Reports Interim Results From Critical Limb Ischemia Trial 68
24 Feb 2010 New Study Demonstrates Effectiveness of Prochymal as a Rescue Therapy for Pediatric Patients with Severe Graft vs. Host Disease 70
23 Feb 2010 Idera Pharmaceuticals Presents Mechanism of Action Data on IMO-3100, a Novel Toll-like Receptor Antagonist for Autoimmune Diseases, at Keystone Symposium 51
22 Feb 2010 Histostem Participates in Clinical Trials Demonstrating the Effective Use of Its Proprietary Stem Cells in the Treatment of Cirrhosis of the Liver 101
22 Feb 2010 Alnylam Initiates Phase IIb Clinical Trial of ALN-RSV01 in Adult Lung Transplant Patients Infected with Respiratory Syncytial Virus (RSV) Infection 56
18 Feb 2010 Dynavax and GlaxoSmithKline Select Clinical Candidate in the Endosomal TLR Inhibitor Program 250
16 Feb 2010 Athersys Announces Completion of Patient Enrollment in Phase I Study of Multistem(R) in Acute Myocardial Infarction 65
16 Feb 2010 Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 85
14 Feb 2010 Idera Pharmaceuticals Presents Preclinical Hyperlipidemia Data on a Toll-like Receptor Antagonist at Keystone Symposium 67
10 Feb 2010 Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint 117
10 Feb 2010 StemCells, Inc. Announces First Human Neural Stem Cell Transplant in Landmark Myelination Disorder Trial 83
10 Feb 2010 ReNeuron receives final regulatory approval to commence landmark stroke clinical trial in UK 127
10 Feb 2010 Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 61
04 Feb 2010 AVI BioPharma GLP Safety Pharmacology and Genotoxicity Evaluations of AVI-4658 for Duchenne Muscular Dystrophy Published in the International Journal of Toxicology 118
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 967

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

RNA Therapeutics
Order Now

Subscribe La Merie Biologics